Preclinical models have demonstrated that the combination of PD-1 blockade and 4-1BB agonists significantly improves tumor infiltration by effector T cells and reduces the suppressive influence of regulatory Tregs and myeloid-derived suppressor cells (MDSCs). Here, TNFRSF9 is linked to neoplasm.